Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.26 USD
+0.16 (3.90%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $4.24 -0.02 (-0.47%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 1 - 20 ( 395 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q4/FY23: Pivotal PK Readout for Anaphylm in March, NDA Filing Before YE:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Aquestive Therapeutics Management Access Webinar Invite - Feb. 23 @ 11AM ET
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Phase 3 Trial Patient Dosing Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q3: Pivotal PK Study for Anaphylm Set to Initiate in Q4:23, Readout in Q1:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Top- and Bottom-Line 3Q23 Beat; Debt Favorably Refinanced; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Positive FDA Feedback Puts Anaphylm On-Track to Topline Readout in Q1:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Business Update Provided; Anaphylm Development on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm - Competitor neffy Hits Snag; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Development Plan Unaffected by neffy CRL; Libervant 2-5yo NDA Accepted
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Pivotal Protocol Submitted to FDA; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q2:23 Financials; Pivotal PK Trial Protocol for Anaphylm Submitted to the FDA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Additional Anaphylm Pharmacokinetic Data Released; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Crossover Study Validates Dosing Instructions; Pivotal PK Study in Q4:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A